What is claimed is:

1. A compound of the formula



or a pharmaceutically acceptable salt thereof, wherein

is a 4-8 membered monocyclic ring or 7-12 membered bicyclic ring; which ring is optionally saturated or unsaturated, which ring is optionally substituted with one or more substituent selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, thioalkyl, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and -$(CH_2)_n$ COR wherein n is 0-2 and R is hydroxy, alkoxy, alkyl or amino;

A^1 is a 5-9 membered monocyclic or 7-14 membered polycyclic heterocycle of the formula



containing at least one nitrogen atom and optionally 1 to 4 heteroatoms or groups, selected from O, N, S, SO_2 or CO; optionally saturated or unsaturated; optionally substituted by one or more R^k selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, thioalkyl, haloalkyl, cyano, amino, alkylamino, halogen,

acylamino, sulfonamide and -COR wherein R is hydroxy, alkoxy, alkyl or amino;



include the following heterocyclic ring systems containing at least one nitrogen atom:



B2 B3 B4

wherein Z_a is H, alkyl, alkoxy, hydroxy, amine, alkylamine, dialkylamine, carboxyl, alkoxycarbonyl, hydroxyalkyl, halogen or haloalkyl and R^1 is H, alkyl, alkoxyalkyl, acyl, haloalkyl or alkoxycarbonyl, pyridylamino, imidazolylamino, morpholinopyridine, tetrahydronaphthyridine, oxazolylamino, thiazolylamino, pyrimidinylamino, quinoline, isoquinoline, tetrahydroquinoline, imidazopyridine, benzimidazole, pyridone or quinolone;

The following heteroaryls include the ring systems described above;



for the pyridyl derived heterocycle, the substituents X_4 and X_5 are selected from the group consisting of H, alkyl, branched alkyl, alkylamino, alkoxyalkylamino, haloalkyl, thioalkyl, halogen, amino, alkoxy, aryloxy, alkoxyalkyl, hydroxy, cyano or acylamino groups; substituents X_4 and X_5 can be methyl, methoxy, amine, methylamine, trifluoromethyl, dimethylamine, hydroxy, chloro, bromo, fluoro and cyano. X_6 may be H, alkyl, halogen, alkoxy, hydroxy, and haloalkyl; the pyridyl ring can be fused with a 4 - 8 membered ring, optionally saturated or unsaturated; these ring systems include tetrahydronaphthyridine, quinoline, tetrahydroquinoline, azaquinoline, morpholinopyridine, imidazo-pyridine; the monocyclic ring systems such as imidazole, thiazole, oxazole, pyrazole may contain an amino or alkylamino substituent at any position within the ring;

when Z_1 of Formula I is CO or SO_2, the linkage A^1-Z_2 of Formula I includes the heterocycle derived ring systems: pyridine, imidazole, thiazole, oxazole, benzimidazole, imidazopyridine and heterocycles for A^1-Z_2 include :



B = NH, O, S
R = H, Me



B = NH, O, S
R = H, Me



B = NH, O, S
R = H, Me



B = NH, O, S
R = H, Me



B = NH, O, S
R = H, Me



B = N, CH
R = H, Me



B = N, CH
R = H, Me



B = NH, O, S
R = H, Me



B = N, CH
R = H, Me

wherein X_4 is as defined above.

or A^1 is



wherein Y^1 is selected from the group consisting of N-R^2, O, and S;

R^2 is selected from the group consisting of H; alkyl; aryl; hydroxy; alkoxy; cyano; alkenyl; alkynyl; amido; alkylcarbonyl; arylcarbonyl; alkoxycarbonyl; aryloxycarbonyl; haloalkylcarbonyl; haloalkoxycarbonyl; alkylthiocarbonyl; arylthiocarbonyl; acyloxymethoxycarbonyl;

R^2 taken together with R^7 forms a 4-12 membered dinitrogen containing heterocycle optionally substituted with one or more substituent selected from the group consisting of lower alkyl, thioalkyl, alkylamino, hydroxy, keto, alkoxy, halo, phenyl, amino, carboxyl or carboxyl ester, and fused phenyl;

or R^2 taken together with R^7 forms a 4-12 membered heterocycle containing one or more heteroatom selected from O, N and S optionally unsaturated;

or R^2 taken together with R^7 forms a 5 membered heteroaromatic ring fused with a aryl or heteroaryl ring;

R^7 (when not taken together with R^2) and R^8 are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; aralkyl; amino; alkylamino; hydroxy; alkoxy; arylamino; amido, alkylcarbonyl, arylcarbonyl; alkoxycarbonyl; aryloxy; aryloxycarbonyl; haloalkylcarbonyl; haloalkoxycarbonyl; alkylthiocarbonyl; arylthiocarbonyl; acyloxymethoxycarbonyl; cycloalkyl; bicycloalkyl; aryl; acyl; benzoyl;

or NR^7 and R^8 taken together form a 4-12 membered mononitrogen containing monocyclic or bicyclic ring optionally substituted with one or more substituent selected from lower alkyl, carboxyl derivatives, aryl or hydroxy and wherein said ring optionally contains a heteroatom selected from the group consisting of O, N and S;

R^5 is selected from the group consisting of H and alkyl;

or

A^1 is 

wherein Y^2 is selected from the group consisting of alkyl; cycloalkyl; bicycloalkyl; aryl; monocyclic heterocycles;

Z_1 is selected from the group consisting of CH_2, CH_2O, O, N, CO, S, SO, SO_2,  and NR_k wherein R_k is selected from H or lower alkyl;

Z_2 is a 1-5 carbon linker optionally containing one or more heteroatom selected from the group consisting of O, S and N; alternatively Z_1 - Z_2 may further contain a carboxamide, sulfone, sulfonamide, alkenylene, alkynylene, or acyl group;

wherein the carbon and nitrogen atoms of Z_1 - Z_2 are optionally substituted by alkyl, alkoxy, thioalkyl, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl or acylamino;

wherein Z_2 - Z_1 is attached to 

at the para or meta position relative to the X_1 substituent;

n is an integer 1 or 2;

R^c is selected from the group consisting of hydrogen; alkyl; halogen, hydroxy, nitro, alkoxy, amino, haloalkyl, aryl, heteroaryl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, thioalkyl, alkylamino, arylamino, alkylsulfonylamino, acyl, acylamino, sulfonyl, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, alkynylalkyl, carboxy, alkoxycarbonyl, carboxamido, cyano, and $-(CH_2)_n$ COR wherein n is 0-2 and R is selected from hydroxy, alkoxy, alkyl and amino;

X_1 is selected from the group consisting of -O-, CO, SO_2, NR^m and $(CHR^p)_q$; wherein R^m is H or alkyl; R^p is H, alkyl; alkoxy or hydroxy; q is 0 or 1;

X_2 is selected from the group consisting of $-CHR^e-$, CO, SO_2, O, NR^f and S; wherein R^f is H or alkyl;

R^e is selected from the group consisting of H, alkyl, hydroxy and alkoxy;

X or Y are independently selected from the group consisting of $-CR^g-$ or -N- wherein R^g is selected from the group consisting of H, alkyl, haloalkyl, fluoro, alkoxyalkyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkylsulfone, hydroxyalkyl, hydroxy, alkoxy, and carboxyalkyl;

optionally the group $X-X_2-Y$ contains a moiety selected from the group consisting of acyl, alkyl, amino, ether, thioether, sulfone and olefin;



forms a 3-8 membered monocyclic ring system; or an 8-11 membered bicyclic system; optionally saturated or unsaturated; the monocyclic ring system optionally containing 1-2 heteroatoms selected from N, O and S; the bicyclic ring system optionally containing 1-4 heteroatoms selected from N, O and S, or optionally containing the group such as SO_2 or CO; and optionally substituted with one or more substituent selected from the group consisting of alkyl, halogen, cyano, carboalkoxy, haloalkyl, alkoxyalkyl, alkylsulfone, aryl, heteroaryl, arakyl, heteroarakyl, or alkoxy;

R^b is X_3 - R^h wherein X_3 is selected from the group consisting of O, S and NR^j wherein R^h and R^j are independently selected from the group consisting of H, alkyl, acyl, aryl, aralkyl and alkoxyalkyl; and

and n is 0 or 1.

2. A compound according to the claim 1,



wherein

A^1, Z_1, Z_2, R^b, R^c, are as described in claim 1;

X_1 is $(CHR^p)_q$; wherein q = 0;

B is a 3-, 4-, or a 5-membered ring obtained by combining X-X_2-Y;

A is a phenyl ring substituted with R^c;

n = 1

3. A compound according to the claim 2,



wherein the ring B is a 3-member cyclopropyl ring;

Y = CR^g;

wherein R^g is selected from the group consisting of H, alkyl, haloalkyl, alkoxyalkyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkylsulfone, hydroxyalkyl, hydroxy, alkoxy, and carboxyalkyl;

A is a phenyl ring substituted with R^c;

R^b = OH

4. A compound according to the claim 3 wherein R^g is selected from the following substituents/groups



R_1 = H, alkyl, OMe, OH, halogen

X = CH_2, O



R_1 = H, alkyl, OMe, OH, halogen



R_1 = H, alkyl, OMe, OH, halogen

X = NH, NMe, O, S



R_1 = H, Me



R_1 = H, Me



R_1 = H, alkyl, OMe, OH, halogen
R = H, Me

H, alkyl, CH_2B_1R (B_1 = O, SO_2, S, CO; R = alkyl, aryl), CH_2OH, R = alkyl, aryl

CH_2R_1 (R_1 = aryl, heteroayl)

5. A compound according to the claim 3 wherein A^1 is selected from the following ring systems



X = CH_2, O, S, SO_2, CO, CF_2, CMe_2
R = H, Me, OMe, OH



X = CH_2, O, S, SO_2, CO, CF_2, CMe_2
R = H, Me, OMe, OH



X = CH_2, O, S, SO_2, CO, CMe_2
R = H, Me, OMe, OH



X = H, alkyl, acyl,
R = H, Me, OH, alkoxyalkyl



R = H, Me, OMe, OH







6. A compound according to the claim 3 wherein ring A is a phenyl ring, and the side chains containing Z_1-Z_2 and X_1-X are connected para to each other.

7. A compound according to the claim 6 wherein the phenyl ring is optionally substituted with one or more substituents selected from the group consisting of alkyl; halogen, hydroxy, alkoxy, haloalkyl,

aryl, heteroaryl, alkoxyalkyl, sulfonamide, methylenedioxy, ethylenedioxy, alkynyl, and alkynylalkyl;

8. A compound according to the claim 6 wherein Z_1 is selected from the group consisting of CH_2, CH_2O, O, NR_k, CO, S, SO, and SO_2. R_k is as defined in claim 1

9. A compound according to the claim 6 wherein A^1 is selected from the following ring systems



10. A compound according to the claim 1,



wherein

A^1, Z_1, Z_2, R^b, R^c, are as described in claim 1;

X_1 is $(CHR^p)_q$; wherein q = o;

A is a phenyl ring substituted with R^c

B is a 3-member ring obtained by combining X-X_2-Y;

n = 1

R_m and R_n are selected from the group consisting of H, alkyl, halogen, alkoxy, haloalkyl, alkoxyalkyl, alkylsulfone, cyano, carboalkoxy, aryl, heteroaryl, aralkyl and heteroaralkyl. R_m and R_n may from a spirocyclic ring system.

11. A compound according to the claim 10 wherein A^1 is selected from the following ring systems:



X = CH_2, O, S, SO_2, CO, CF_2, CMe_2
R = H, Me, OMe, OH



X = CH_2, O, S, SO_2, CO, CF_2, CMe_2
R = H, Me, OMe, OH



X = CH_2, O, S, SO_2, CO, CMe_2
R = H, Me, OMe, OH



X = H, alkyl, acyl,
R = H, Me, OH,
alkoxyalkyl



R = H, Me,
OMe, OH







12. The intermediates of formula 2 for their utility in the synthesis of αvβ3 and/or αvβ5 integrin antagonists.



2

13. A compound according to Claim 1 selected from the group consisting of :

2-[4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropaneacetic acid
2-[4-[3-(2-pyridinylamino)propoxy]phenyl] cyclopentaneacetic acid
3-[4-[3-(2-pyridinylamino)propoxy]phenyl] cyclopentaneacetic acid
2,2-difluoro-3-[4-[3(2-pyridinylamino)propoxy]phenyl]cyclopropane-acetic acid
(2-{4-[2-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid
2-[3-methyl-4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropane-acetic acid

(2-{4-[3-(1-*H*-Pyrazol-3-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(2-{3-Fluoro-4-[3-(1-*H*-pyrazol-3-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Methyl-2-{4-[2-(6-methylamino-pyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

(2-{4-[2-(6-Ethylamino-pyridin-2-yl)-ethoxy]-phenyl}-1-methyl-cyclopropyl)-acetic acid

[2-(4-{2-[6-(2-Methoxy-ethylamino)-pyridin-2-yl]-ethoxy}-phenyl)-1-methyl-cyclopropyl]-acetic acid

[2-(4-{2-[6-(3-Methoxy-propylamino)-pyridin-2-yl]-ethoxy}-phenyl)-1-methyl-cyclopropyl]-acetic acid

(2-{4-[2-(6-Acetylamino-pyridin-2-yl)-ethoxy]-phenyl}-1-methyl-cyclopropyl)-acetic acid

[1-Methyl-2-(4-{2-[6-(2,2,2-trifluoro-ethylamino)-pyridin-2-yl]-ethoxy}-phenyl)-cyclopropyl]-acetic acid

(2-{4-[2-(6-Ethylamino-pyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

[2-(4-{2-[6-(2-Methoxy-ethylamino)-pyridin-2-yl]-ethoxy}-phenyl)-cyclopropyl]-acetic acid

[2-(4-{2-[6-(2,2,2-Trifluoro-ethylamino)-pyridin-2-yl]-ethoxy}-phenyl)-cyclopropyl]-acetic acid

[2-(4-{2-[6-(3-Methoxy-propylamino)-pyridin-2-yl]-ethoxy}-phenyl)-cyclopropyl]-acetic acid

(2-{4-[2-(6-Acetylamino-pyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claims 2-13 and a pharmaceutically acceptable carrier.

2-[2-methoxy-4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropane-acetic acid

2-[2-methyl-4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropane-acetic acid

2-[3-fluoro-4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropaneacetic acid

2-[2-fluoro-4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropaneacetic acid

2-[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]cyclopropane-acetic acid

2-[4-[2-(3,4-dihydro-2*H*-pyrido[3,2-*b*]-1,4-oxazin-6-yl)ethoxy]phenyl]-cyclopropaneacetic acid

3-[4-[3-(2-pyridinylamino)propoxy]phenyl]cyclobutaneacetic acid

(2-{2-Methoxy-4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(2-{2-Fluoro-4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(2-{2-Acetoxy-4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Methyl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Methoxymethyl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Methanesulfonylmethyl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Pyridin-3-yl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Benzo[1,3]dioxole-5-yl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(1-(2,3-Dihydro-benzofuran-6-yl)-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Isoxazol-3-yl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Isoxazol-5-yl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Oxazol-5-yl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(2-{4-[3-(Pyridin-2-ylamino)-propoxy]-phenyl}-1-thiazol-5-yl-cyclopropyl)-acetic acid

(1-Methyl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Methoxymethyl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Methanesulfonylmethyl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Pyridin-3-yl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

(1-(2,3-Dihydro-benzofuran-6-yl)-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Benzo[1,3]dioxol-5-yl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Isoxazol-3-yl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Isoxazol-5-yl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

(1-Oxazol-5-yl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid

(2-{4-[2-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-1-thiazol-5-yl-cyclopropyl)-acetic acid

(2-{4-[3-(1-*H*-Imidazol-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(2-{3-Fluoro-4-[3-(1-*H*-imidazol-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(2-{3-Fluoro-4-[3-(3-*H*-imidazol-4-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

(2-{4-[3-(3-*H*-Imidazol-4-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid

16. A pharmaceutical composition comprising a therapeutically effective amount of atleast one compound of claim 1 and a pharmaceutically acceptable carrier/or additive and optionally other active ingredient

17. A pharmaceutical composition comprising a therapeutically effective amount of atleast one compound of claims 2-15 and a pharmaceutically acceptable carrier/or additive and optionally other active ingredient

18. .A method for treating conditions mediated by the $\alpha_V\beta_3$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_V\beta_3$ inhibiting amount of a compound of Claim 1.

19. A method for treating conditions mediated by the $\alpha_V\beta_3$ integrin in a mammal in need of such treatment compirisng administering an effective $\alpha_V\beta_3$ inhibiting amount of a compound of Claims 2-13.

20. The method according to Claim 16 wherein the condition treated is tumor metastasis.

21. The method according to Claim 17 wherein the condition treated is tumor metastasis.

22. The method according to Claim 16 wherein the condition treated is solid tumor growth.

23. The method according to Claim 17 wherein the condition treated is solid tumor growth.

24. The method according to Claim 16 wherein the condition treated is angiogenesis.

25. The method according to Claim 17 wherein the condition treated is angiogenesis.

26. The method according to Claim 16 wherein the condition treated is osteoporosis.

27. The method according to Claim 17 wherein the condition treated is osteoporosis.

28. The method according to Claim 16 wherein the condition treated is humoral hypercalcemia of malignancy.

29. The method according to Claim 17 wherein the condition treated is humoral hypercalcemia of malignancy.

30. The method according to Claim 16 wherein the condition treated is smooth muscle cell migration.

31. The method according to Claim 17 wherein the condition treated is smooth muscle cell migration.

32. The method according to Claim 16 wherein restenosis is inhibited.

33. The method according to Claim 17 wherein restenosis is inhibited.

34. The method according to Claim 16 wherein atherosclerosis is inhibited.

35. The method according to Claim 17 wherein atherosclerosis is inhibited.

36. The method according to Claim 16 wherein macular degeneration is inhibited.

37. The method according to Claim 17 wherein macular degeneration is inhibited.

38. The method according to Claim 16 wherein retinopathy is inhibited.

39. The method according to Claim 17 wherein retinopathy is inhibited.

40. The method according to Claim 16 wherein arthritis is inhibited.

41. The method according to Claim 17 wherein arthritis is inhibited.

42. A method for treating conditions mediated by the $\alpha_V\beta_5$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_V\beta_5$ inhibiting amount of a compound of Claim 1.

43. A method for treating conditions mediated by the $\alpha_V\beta_5$ integrin in a mammal in need of such treatment compirisng administering an effective $\alpha_V\beta_5$ inhibiting amount of a compound of Claim 2.

44. The method according to Claim 40 wherein the condition treated is tumor metastasis.

45. The method according to Claim 41 wherein the condition treated is tumor metastasis.

46. The method according to Claim 40 wherein the condition treated is solid tumor growth.

47. The method according to Claim 41 wherein the condition treated is solid tumor growth.

48. The method according to Claim 40 wherein the condition treated is angiogenesis.

49. The method according to Claim 41 wherein the condition treated is angiogenesis.

50. The method according to Claim 40 wherein the condition treated is osteoporosis.

51. The method according to Claim 41 wherein the condition treated is osteoporosis.

52. The method according to Claim 40 wherein the condition treated is humoral hypercalcemia of malignancy.

53. The method according to Claim 41 wherein the condition treated is humoral hypercalcemia of malignancy.

54. The method according to Claim 40 wherein the condition treated is smooth muscle cell migration.

55. The method according to Claim 41 wherein the condition treated is smooth muscle cell migration.

56. The method according to Claim 40 wherein restenosis is inhibited.

57. The method according to Claim 41 wherein restenosis is inhibited.

58. The method according to Claim 40 wherein atheroscelorosis is inhibited.

59. The method according to Claim 41 wherein atheroscelorosis is inhibited.

60. The method according to Claim 40 wherein macular degeneration is inhibited.

61. The method according to Claim 41 wherein macular degeneration is inhibited.

62. The method according to Claim 40 wherein retinopathy is inhibited.

63. The method according to Claim 41 wherein retinopathy is inhibited.

64. The method according to Claim 40 wherein arthritis is inhibited.

65. The method according to Claim 41 wherein arthritis is inhibited.